Upvote
Downvote
Director, Immunogenicity & Biomarker
Share Job
- Suggest Revision
$235,000 - $278,000 a year
Full-time
- We seek to unlock the full potential of gene therapy using our platform, Therapeutic Vector Evolution (TVE), which combines the power of directed evolution with our approximately one billion synthetic AAV capsid-derived sequences to invent evolved vectors for use in our products.
- We have built a deep portfolio of AVV-based gene therapy product candidates, with five product candidates in clinical trials: 4D-150 for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), 4D-710 for the treatment of cystic fibrosis lung disease, 4D-310 for the treatment of Fabry disease cardiomyopathy, 4D-125 for the treatment of X-linked retinitis pigmentosa (XLRP), and 4D-110 for the treatment of choroideremia.
- The group performs immunogenicity assessments, biomarker measurements, molecular assays, and exploratory clinical research during AAV therapeutics development.
- Devising bioanalytical portfolio strategy, immunogenicity risk assessments, and biomarker plans for investigational AAV therapeutics programs
- Leveraging a strong understanding of bioanalytical assays to analyze and interpret data in order to drive key decisions in AAV product development, e.g., FIH dose selection
Active Job
Updated YesterdaySimilar Job
Relevance
Active